Adding methylene blue to onabotulinum toxin A (BTX-A) solution for thetreatment of overactive bladder (OAB) facilitates observation of the procedureand assessment of drug distribution, researchers reported online ahead ofprint in the Scandinavian Journal of Urology.

Michal Szczypior, MD, and colleagues at the Medical University of Gdansk inPoland tested this approach in 30 patients (24 women and 6 men) with OAB whoqualified for BTX-A injections. Each patients received 100 IU of BTX-A dissolvedin 9.5 mL of 0.9% sodium chloride solution, with 0.5 mL of methylene blue added.Over the course of 600 injections, the investigators reported that they were unableto observe the exact distribution of the solution in only 43 injections in 7 patients.They found no pharmacologic interactions between methylene blue and BTX-A.

Related Articles

Continue Reading